Molbio Diagnostics Ltd
- Market cap
- ₹ 14,263 Cr.
- P/E
- 90.5x
- P/B
- 12.15x
- 52-week range
- 926.35 – 1,686.8
- ROE
- 14%
- ROCE
- 18%
- Debt / equity
- 0.38
- Sector
- Healthcare Equipment & Supplies
- Industry
- Medical Equipment & Supplies
- Listed on
- NSE, BSE
About
Molbio Diagnostics Limited is an India-based point-of-care diagnostics company. The Company is engaged in the business of manufacturing chip based diagnostic devices, chips and reagents, X-radiation equipment, single/dual detector solutions, developing diagnostic devices, performing tests in the bio-sensing domain, digital pathology, among others. Its portable and battery operated Truenat platform facilitates diagnosis using its disease-specific Truenat test kits within an hour and enables screening and diagnosis for over 30 diseases. Its Truenat platform comprises two portable instruments - the Trueprep universal nucleic acid extraction device, which performs fully automated sample preparation and the Truelab analyzer, which conducts real-time PCR. The Truenat Test kits consist of three main components: chips, cartridges, and reagents. It also offers devices enabling radiology, digital pathology, and breast health screening.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Medical Equipment & Supplies: 25 companies →Molbio Diagnostics Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)90.5 against a typical 28.7: pricier than most peers (1st = cheapest).24th of 25
- Size₹ 14,262.7 Cr. market value against a typical ₹ 238.1 Cr. (1st = largest).2nd of 24
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 5 Sep 2026 | Financial Results | To consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30 June 2026. |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Sales | 95 | 439 | 399 |
| Expenses | 105 | 332 | 308 |
| Operating Profit | −10 | 107 | 92 |
| OPM % | −10% | 24% | 23% |
| Other Income | 1 | 3 | 1 |
| Interest | 2 | 9 | 9 |
| Depreciation | 7 | 10 | 8 |
| Profit before tax | −17 | 91 | 76 |
| Tax % | −23% | 28% | 25% |
| Net Profit | −13 | 66 | 57 |
| EPS in Rs | −5.95 | 5.83 | 5.02 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 1%
- 3 Years
- 59%
- TTM
- 35%
- 10 Years
- —
- 5 Years
- −19%
- 3 Years
- 111%
- TTM
- 1%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 16%
- 3 Years
- 15%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Molbio Diagnostics Ltd | ₹ 1,304.40 | ₹ 14,263 Cr. | 90.5x | 12.2x | 14% | — |
| Kinetic Trust | ₹ 48.51 | ₹ 16 Cr. | — | — | — | — |
Management
- Sriram Natarajan
- Chief Executive Officer, Director
- Amitabh Kumar Jha
- Chief Financial Officer
- Manmeet Singh
- Chief Financial Officer
- Darshan Raghunath Karekar
- Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.